Dr. Koontz on study of dose-escalated RT plus androgen suppression in prostate cancer

SAP Partner | <b>GenesisCare</b>

In this video, Bridget F. Koontz, MD, provides an expert opinion on the methods and findings of the study, “Dose-escalated radiotherapy alone or in combination with short-term androgen suppression for intermediate risk prostate cancer: outcomes from the NRG Oncology/RTOG 0815 randomized trial,” presented recently at the 2021 American Society for Radiation Oncology Annual Meeting. Koontz is a radiation oncologist, US chief medical officer, and deputy global chief medical officer for GenesisCare.